All In Biotech

Drug Trial Radar · NCT07854652

BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

An Exploratory Clinical Study of Ifupinostat Hydrochloride for Injection (BEBT-908) Monotherapy in Relapsed/Refractory or Measurable Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia With MEF2D Rearrangement

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Aug 30, 2028

Study completion Aug 30, 2030

Sponsor

Lead sponsor
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guangzhou BeBetter Med Co., Ltd
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement. The study will include patients with relapsed or refractory disease and patients who are in morphologic remission but still have measurable residual disease (MRD). The main purpose of the study is to evaluate the preliminary anti-leukemia activity of BEBT-908 in patients with relapsed or refractory disease and its ability to reduce or eliminate residual leukemia in patients with MRD-positive disease. The study will also assess the depth and duration of response, survival outcomes, subsequent treatment such as stem cell transplantation or CAR-T therapy, and the safety and tolerability of BEBT-908. Approximately 10 to 15 participants aged 14 to 75 years are planned to be enrolled. All participants will receive BEBT-908 by intravenous infusion at 18.5 mg/m² on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle for up to two cycles. Bone marrow morphology, flow cytometry MRD, and MEF2D fusion transcript levels will be evaluated during the study to assess treatment response.

Conditions

  • B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Interventions

  • Ifupinostat HydrochlorideDrug

    Ifupinostat hydrochloride (BEBT-908) will be administered intravenously at a dose of 18.5 mg/m² on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle for up to 2 cycles. Each dose will be administered as a constant-rate intravenous infusion over 30 ± 5 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate in Participants With Relapsed/Refractory DiseaseTime frame: From first dose through Cycle 2 Day 21 ± 3 days (approximately 6 weeks)
  2. Complete MRD Response Rate in Participants With MRD-Positive DiseaseTime frame: From first dose through Cycle 2 Day 21 ± 3 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The first affiliated hospital of soochow university

    Suzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.